You are here: Industry Insights > therapeutics

News List

Eidos Therapeutics raises $106M IPO to advance ATTR med fiercebiotech
June 25, 2018
Rare disease biotech Eidos Therapeutics priced its IPO at $17 a share, hauling in about $106.3 million to push its treatment for transthyretin (TTR) amyloidosis through the clinic.
PTC Therapeutics’ results in SMA has Biogen nervous pharmafile
June 22, 2018
Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that treatment is pretty central to the biotech’s portfolio, bringing in $364 million in revenue in the first quarter.
BridgeBio Launches CoA Therapeutics contractpharma
June 19, 2018
BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray drugs
May 31, 2018
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed today that an expert panel convened by the U.S. Food and Drug Administration
CERENIS Therapeutics and University of North Texas Health Science Center Announce a Strategic Initiative to Develop New HDL-Based Pharmaceutical Products firstwordpharma
May 30, 2018
CERENIS Therapeutics (Paris:CEREN)(FR0012616852 - CEREN - PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases,
Celgene Partners with Prothena Therapeutics in Potential $2B Deal biospace
March 22, 2018
Shares of Prothena Corporation plc have shot up more than 18 percent in premarket trading this morning
Immuno-oncology Therapeutics Market to Reach $3.9 Billion by 2022, Finds Frost & Sullivan prnasia
March 20, 2018
Frost & Sullivan's latest analysis, Immuno-oncology Therapeutics Market -- Adoptive T-cell Therapies, Forecast to 2022, finds that the market is expected to generate revenues of $3.9 billion by 2022
Novogen becomes Kazia Therapeutics prnasia
November 20, 2017
The word 'Kazia' is derived from 'Kaizen', a Japanese business philosophy of continuous improvement of working practices and personal efficiency. Read more about the Kazia Therapeutics brand.
Protagonist Therapeutics Initiates PTG-200 Phase 1 Trial americanpharmaceuticacreview
November 10, 2017
Protagonist Therapeutics announced the initiation of dosing in a Phase I healthy volunteer study of PTG-200, a potential first-in-class, gastrointestinal-restricted, oral peptide interleukin (IL)-23 receptor antagonist.
Lupin to acquire Symbiomix Therapeutics expressbpd
October 12, 2017
Lupin announced that its US subsidiary, Lupin has acquired Symbiomix Therapeutics. Lupin had entered into an option to acquire the company earlier this year.

Previous page 1 2 3 4 5 Next page